Dr. Nicole Drezner is a pediatric oncologist and the Deputy Division Director of the Division of Oncology 2 (DO2) at the U.S. Food and Drug Administration (FDA). She joined the thoracic and head and neck oncology team in DO2 as a clinical reviewer in 2016, became team lead of the thoracic and head and neck team in 2020, and began her role as Deputy Division Director in 2022. Dr. Drezner completed her residency in pediatrics at Cohen Children’s Medical Center of NY. She was selected to serve as chief resident for one year after her pediatric residency and then moved to Washington, DC for her pediatric hematology/oncology fellowship at Children’s National Hospital. She remained at Children’s National Hospital for an additional year as a pediatric neuro-oncology fellow prior to joining the FDA.

Nicole Drezner

Research and Publications

Akinboro O, Drezner N, Amatya A, et al. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients with Resectable Non-Small Cell Lung Cancer. J Clin Oncol. 2023; 41(17): 3249-3259.

Barbato M, Nashed J, Bradford D, et al. FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation positive low grade glioma. Clin Cancer Res. CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.

Duke ES, Stapleford L, Drezner N, et al. FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clin Cancer Res. 2023; 29(3): 508-512.

Nakajima EC, Drezner N, Li X, et al. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-3074.

Koch AL, Vellanki PJ, Drezner N, et al. FDA Approval Summary: Osimertinib for the Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clin Cancer Res. 2021; 27(24): 6638-6643.

Ahmed M, Patel C, Drezner N, et al. Summary of 2018 ASCPT Annual Meeting Symposium on Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development. Clin Transl Sci. 2020; 13(1): 31-40.

Blumenthal GM, Bunn PA Jr., Chaft JE, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018;13(12): 1818-1831.

Drezner N, Hardy KK, Wells E, et al. Treatment of pediatric cerebral radiation necrosis: a systematic review. J Neurooncol. 2016; 130(1):141-148.

Drezner NL and Packer RJ. The impact of molecular analysis on the survival of children with embryonal tumors. Translational Pediatrics. 2016; 5(1):5-8.